| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
VivoSim Labs, Inc.$1.13
0 (0%)
Market Cap
3.55 M
EPS
0.47
P/E Ratio
2.92 $
Value Trade
44.34 K
SEC Financials
Q4 2025Dilution Risk
Revenue
26.00 K
R&D Expenses
1.14 M
Total Assets
6.96 M
Total Liabilities
2.52 M
Equity
4.44 M
D/E Ratio
12,345
4.62 %
Week
-4.9 %
1 Month
-30.26 %
3 Month
-34.93 %
6 Month
-99.87 %
5 Year
-100 %
All Time
Cash Data
Cash Position
4.29 M
Monthly Burn
917.00 K
Runway
0.5 mo
Burn Trend
StableSEC Filing
Feb 11, 2026
Overview
Volume
64.82 K
52 Week Range
1.22 - 5.30
% held by Insiders
12.67 %
% held by Institutions
3.75 %
Enterprise Value
70.83 K
Total Shares
2.61 M
Short %
1.31 %
Float Shares
2.54 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VIVS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VivoSim Labs, Inc. (VIVS) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
VIVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VIVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VIVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VIVS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
VIVS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VIVSVivoSim Announces Pricing of up to a $4 Million Public Offering
VivoSim Labs, Inc. has announced a public offering of up to $4 million, with an initial closing of $3 million expected on April 1, 2026. The offering includes common stock and pre-funded warrants, with additional funding contingent on certain conditions. Joseph Gunnar & Co., LLC is the exclusive placement agent for this offering.
Read more →VIVSVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
VivoSim Labs announced the validation of its NAMkind liver and intestine models for predicting toxicity in antibody drug conjugates (ADCs) at the Society of Toxicology meeting. The models have shown a strong correlation with clinical outcomes, enabling better selection of ADC candidates. The company aims to enhance drug development by minimizing side effects through these innovative methodologies.
Read more →VIVSVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
VivoSim Labs has appointed Dr. Arumugham (Ragoo) Raghunathan as Vice President of Global Sales. Based in the Greater Boston area, he will lead efforts to expand commercial partnerships and enhance the delivery of the company's liver and gastrointestinal toxicity solutions. Dr. Raghunathan's experience in drug discovery and safety assessment will be pivotal in helping clients make informed decisions in drug development.
Read more →VIVSVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
VivoSim Labs, Inc. will present new data on its NAMkind models for predicting toxicity of antibody drug conjugates at the Society of Toxicology meeting in San Diego. The models have shown a close correlation with clinical safety outcomes, indicating their potential to optimize ADC candidates. This presentation marks a significant advancement in the application of NAMs in drug development.
Read more →VIVSVivoSim Labs Appoints Tony Lialin as Chief Commercial Officer Veteran commercial leader to scale AI-enabled NAMkind liver and intestine toxicology services in a rapidly growing market San Diego, CA —
VivoSim Labs has appointed Tony Lialin as the new Chief Commercial Officer, tasked with scaling AI-enabled toxicology services for liver and intestine. Lialin brings over two decades of experience in the biotech space, aiming to lead go-to-market strategies and expand the company's service offerings. The firm sees a significant market opportunity in the growing demand for 3D human tissue models and non-animal testing methods. The adoption of such approaches is bolstered by recent regulatory changes, particularly the FDA Modernization Act 2.0.
Read more →VIVSVivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market San Diego, CA –
VivoSim Labs, Inc. has emerged from stealth mode to offer innovative technologies that align with the FDA's initiative to phase out animal testing in drug development. The company introduces non-animal methodologies that provide insights into liver and intestinal toxicology, potentially transforming drug evaluation processes. These advancements could lead to a 50% reduction in clinical trial failures and costs for pharmaceutical companies. With the FDA prioritizing non-animal approaches, VivoSim positions itself to fill a significant market gap.
Read more →VIVSVivoSim to Carry Forward Organovo 3D Bioprinting San Diego, CA –
Organovo Holdings, Inc. announced it will change its name to VivoSim Labs, Inc., effective April 24, 2025. The company's stock will also transition to trade under the new ticker symbol VIVS on the Nasdaq Capital Market. Importantly, existing stockholders need not take any action regarding these changes, and the company’s stock will remain listed under the same CUSIP number. This move is part of their strategy to carry forward their 3D bioprinting legacy technology.
Read more →VIVSOrganovo Provides Update on Cash and Nasdaq Continued Listing Requirements San Diego, CA –
Organovo Holdings, Inc. has provided an update regarding its financial status and compliance with Nasdaq listing requirements as of March 31, 2025. The company reported a preliminary cash balance of approximately $11.3 million and expects to receive a $5M milestone payment related to an upcoming Phase 2 clinical trial. Organovo's stock has been trading above the $1.00 minimum bid price since March 21, 2025, which indicates a strong position for continued listing. However, the financial figures are preliminary and subject to adjustment pending audit completion, raising some uncertainties.
Read more →VIVSOrganovo Provides Business Update San Diego, CA –
Organovo Holdings, Inc. provided a business update indicating a successful sale of its FXR Program to Lilly, which has led to both upfront and anticipated future milestone payments. The company expects to reduce expenses significantly as it pivots from the FXR314 clinic advancement, which allows for better financial positioning moving forward. Moreover, Organovo highlighted the promising performance of FXR314 in 3D human cellular models for inflammatory bowel disease, positioning it for potential future success. The company aims to utilize its capital effectively to explore new therapeutic opportunities.
Read more →VIVSOrganovo Announces Close of the Sale of FXR Program to Eli Lilly and Company San Diego, CA –
Organovo Holdings, Inc. announced the successful sale of its FXR program, including its lead asset FXR314, to Eli Lilly and Company on March 25, 2025. The deal marks a significant transaction for Organovo, which will receive an upfront payment alongside additional milestone payments based on regulatory and commercial achievements of FXR314. Eli Lilly will acquire all rights for worldwide development and will oversee all future clinical advancements related to the FXR program.
Read more →VIVSOrganovo Announces Reverse Stock Split
Organovo Holdings, Inc. has announced a 1-for-12 reverse stock split effective March 20, 2025, to maintain compliance with Nasdaq minimum bid price requirements. The split will reduce the number of outstanding shares from approximately 21.4 million to about 1.8 million, while allowing the company to keep its existing CUSIP number. This decision received prior approval from stockholders at the annual meeting held in November 2024. Stockholders will not need to take action as their accounts will automatically reflect the adjustments caused by the reverse split.
Read more →VIVSOrganovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises San Diego, CA –
Organovo Holdings, Inc. has announced the issuance of 2,967,144 additional shares in connection with warrant exercises and at-the-market stock sales, bringing the total outstanding shares to 20,421,617. The move is expected to generate around $2.3 million in gross proceeds, highlighting investor interest in the company. Organovo is focused on developing innovative treatment methods for inflammatory bowel disease through its proprietary 3D tissue technology.
Read more →VIVSOrganovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company San Diego, CA –
Organovo Holdings, Inc. has announced the acquisition of its FXR program, including the lead asset FXR314, by Eli Lilly and Company. This acquisition marks a significant milestone in the development of treatments for inflammatory bowel disease (IBD). Organovo's Executive Chairman expressed optimism about the partnership, highlighting Lilly's development expertise. Under the transaction, Organovo will receive an upfront payment and milestone payments tied to FXR314's future regulatory and commercial achievements.
Read more →VIVSOrganovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Organovo Holdings, Inc. announced a public offering of 6,562,500 shares priced at $0.80 each, aiming to raise $5.25 million. The offering includes common warrants that are immediately exercisable. The funds are intended to further develop the company's lead molecule, FXR314, which is set for Phase 2 trials in inflammatory bowel disease. The closing of the offering is expected around May 13, 2024, pending customary conditions. This offering follows SEC approval of the related registration statement.
Read more →VIVSCertain statements contained in this presentation or in other documents of Organovo Holdings, Inc. (the “Company” or “Organovo”) and of any of its affiliates, along with certain statements tha
Organovo Holdings has presented forward-looking statements regarding its lead asset FXR314, which is in development for treating Inflammatory Bowel Disease and liver conditions. The data highlights FXR314's efficacy in preclinical models, notably for ulcerative colitis, and outlines upcoming trials aimed at demonstrating its potential benefits. Market opportunities appear strong, particularly in an area with substantial unmet medical needs. However, the company cautions that actual results may vary due to inherent uncertainties and risks in clinical development.
Read more →VIVSOrganovo Announces Postponement of Annual Meeting of Stockholders San Diego, CA
Organovo Announces Postponement of Annual Meeting of Stockholders San Diego, CA - September 6, 2022 - Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human diseas
Read more →VIVSOrganovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents San Diego, CA, February 23, 2022-Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo's founda
Read more →VIVSORGANOVO ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF SHAREHOLDERS DUE TO LACK OF QUORUM Solana Beach, CA.
ORGANOVO ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF SHAREHOLDERS DUE TO LACK OF QUORUM Solana Beach, CA., September 17, 2021 Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that the Company s annual meeting of shareholders, on September 14, 2021, at 9:00 a.m. was conve
Read more →VIVSOrganovo Regains Compliance with Nasdaq Minimum Bid Price Requirement San Diego, CA
Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement San Diego, CA, September 3, 2020 - Organovo Holdings, Inc. ("Organovo" or the "Company") (Nasdaq: ONVO) announced today that it has regained compliance with the minimum bid price requirement for continued list
Read more →VIVSOrganovo Announces One-for-Twenty Reverse Stock Split San Diego
Organovo Announces One-for-Twenty Reverse Stock Split San Diego, August 17, 2020 - Organovo Holdings, Inc. (the "Company") (Nasdaq: ONVO) today announced that it filed a certificate of second amendment to its certificate of incorporation with the Secretary of State of the State
Read more →VIVSOrganovo Announces Termination of Merger Agreement with Tarveda Therapeutics SAN DIEGO--(BUSINESS WIRE)
Organovo Announces Termination of Merger Agreement with Tarveda Therapeutics SAN DIEGO--(BUSINESS WIRE)--April 7, 2020-- Organovo Holdings, Inc. ("Organovo") (Nasdaq: ONVO) announced today that it has terminated the merger agreement with Tarveda Therapeutics, Inc. ("Tarveda"), o
Read more →VIVSOrganovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders
Organovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders SAN DIEGO, CALIFORNIA, March 31, 2020- Organovo Holdings, Inc. ("Organovo") (Nasdaq: ONVO) convened, on March 26, 2020, the special meeting of stockholders (the "Special Meeting") and th
Read more →VIVSOrganovo Holdings, Inc. Announces Adjournment of Special Meeting of Stockholders
Organovo Holdings, Inc. Announces Adjournment of Special Meeting of Stockholders SAN DIEGO, CALIFORNIA, March 27, 2020- Organovo Holdings, Inc. ("Organovo") (Nasdaq: ONVO) convened, on March 26, 2020, the special meeting of stockholders and then adjourned the special meeting of
Read more →VIVSTarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China SciClone granted exclusive license to co-develop and commercialize PEN-866 upon approval in the G
Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China SciClone granted exclusive license to co-develop and commercialize PEN-866 upon approval in the Greater China Region Watertown, MA, March 19, 2020 Tarveda
Read more →VIVSInvestor Relations Organovo Holdings, Inc. +1 (858) 224-1000 ir@organovo.com Organovo Acknowledges Receipt of Proposal Reiterates Commitment to Strategic Review Process
Contact: Investor Relations Organovo Holdings, Inc. Organovo Acknowledges Receipt of Proposal Reiterates Commitment to Strategic Review Process SAN DIEGO - October 2, 2019 - Organovo Holdings, Inc. (NASDAQ: ONVO) ("Organovo") today confirmed that it has received a proposal fr
Read more →VIVSOrganovo Holdings, Inc. +1 (858) 224-1000, ext. 3000 ir@organovo.com
Organovo Holdings, Inc. +1 (858) 224-1000, ext. 3000 ORGANOVO TO EXPLORE STRATEGIC ALTERNATIVES AND IMPLEMENT RESTRUCTURING PLAN SAN DIEGO - August 7, 2019 - Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo") today announced that it has engaged Roth Capital Partners ("Roth") a
Read more →VIVSInvestor & Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com ORGANOVO UPDATES KEY CLINICAL DEVELOPMENT GOALS; COMPANY REPORTS PRELIMINARY FISCAL FOURTH-QUARTER 2019 RESULTS -
Investor & Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com ORGANOVO UPDATES KEY CLINICAL DEVELOPMENT GOALS; COMPANY REPORTS PRELIMINARY FISCAL FOURTH-QUARTER 2019 RESULTS SAN DIEGO - May 22, 2019 - Organovo Holdings, Inc. (NAS
Read more →VIVSInvestor & Press Contact: Steve Kunszabo Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com
Investor & Press Contact: Steve Kunszabo Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com ORGANOVO APPOINTS NEW BOARD MEMBER SAN DIEGO - February 20, 2018 - Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo"), a biotechnolog
Read more →VIVSInvestor & Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com ORGANOVO AFFIRMS KEY CLINICAL DEVELOPMENT GOALS; COMPANY REPORTS FISCAL THIRD-QUARTER 2019 RESULTS - Pre-Investiga
Investor & Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com ORGANOVO AFFIRMS KEY CLINICAL DEVELOPMENT GOALS; COMPANY REPORTS FISCAL THIRD-QUARTER 2019 RESULTS SAN DIEGO - February 7, 2019 - Organovo Holdings, Inc. (NASDAQ:ONVO)
Read more →VIVSInvestor & Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com
Investor & Press Contact: Organovo Holdings, Inc. skunszabo@organovo.com ORGANOVO APPOINTS NEW BOARD MEMBER SAN DIEGO - December 6, 2018 - Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo"), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at
Read more →VIVSInvestor & Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com ORGANOVO AFFIRMS KEY CLINICAL DEVELOPMENT GOALS; COMPANY REPORTS FISCAL SECOND-QUARTER 2019 RESULTS - Pre-Investig
Investor & Press Contact: Organovo Holdings, Inc. skunszabo@organovo.com ORGANOVO AFFIRMS KEY CLINICAL DEVELOPMENT GOALS; COMPANY REPORTS FISCAL SECOND-QUARTER 2019 RESULTS - Pre-Investigational New Drug ("IND") meeting with the FDA expected to be held in calendar 2019 - Sec
Read more →VIVSInvestor & Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com ORGANOVO REPORTS FISCAL FIRST-QUARTER 2019 RESULTS; COMPANY OUTLINES AND EXPANDS KEY CLINICAL DEVELOPMENT GOALS -
Investor & Press Contact: Organovo Holdings, Inc. skunszabo@organovo.com ORGANOVO REPORTS FISCAL FIRST-QUARTER 2019 RESULTS; COMPANY OUTLINES AND EXPANDS KEY CLINICAL DEVELOPMENT GOALS SAN DIEGO - August 9, 2018 - Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo"), a biotechn
Read more →VIVSInvestor & Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com ORGANOVO REPORTS FISCAL FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS; COMPANY ANNOUNCES KEY GOALS FOR FISCAL-YEAR 201
Investor & Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com ORGANOVO REPORTS FISCAL FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS; COMPANY ANNOUNCES KEY GOALS FOR FISCAL-YEAR 2019 -Lead Investigational New Drug ("IND") program for Alpha
Read more →VIVSInvestor Contact: Press Contact: Steve Kunszabo Jessica Yingling Organovo Holdings, Inc. Little Dog Communications +1 (858) 224-1092 +1 (858) 480-2411 skunszabo@organovo.com jessica@litldog.com ORGANOVO ANNOUNCES FISCAL
Investor Contact: Press Contact: Steve Kunszabo Jessica Yingling Organovo Holdings, Inc. Little Dog Communications +1 (858) 224-1092 +1 (858) 480-2411 skunszabo@organovo.com jessica@litldog.com ORGANOVO ANNOUNCES FISCAL THIRD-QUARTER 2018 RESULTS; COMPANY UPDATES FULL-YEAR FISCA
Read more →VIVSInvestor Contact: Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com Jessica Yingling Little Dog Communications +1 (858) 480-2411 jessica@litldog.com ORGANOVO ANNOUNCES FISCAL
Investor Contact: Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com Jessica Yingling Little Dog Communications +1 (858) 480-2411 jessica@litldog.com ORGANOVO ANNOUNCES FISCAL SECOND-QUARTER 2018 RESULTS; COMPANY SHIFTS COMMERCIAL FO
Read more →VIVSInvestor & Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com ORGANOVO ANNOUNCES PRELIMINARY FISCAL SECOND- QUARTER TOTAL REVENUE
Investor & Press Contact: Organovo Holdings, Inc. skunszabo@organovo.com ORGANOVO ANNOUNCES PRELIMINARY FISCAL SECOND- QUARTER TOTAL REVENUE; COMPANY RESTRUCTURES TO IMPROVE OPERATIONAL EFFICIENCY SAN DIEGO - October 4, 2017 - Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo"
Read more →VIVSInvestor Contact: Press Contact: Steve Kunszabo Jessica Yingling, Ph.D. Organovo Holdings, Inc. Little Dog Communications +1 (858) 224-1092 +1 (858) 480-2411 skunszabo@organovo.com jessica@litldog.com ORGANOVO ANNOUNCES
Investor Contact: Press Contact: Steve Kunszabo Jessica Yingling, Ph.D. Organovo Holdings, Inc. Little Dog Communications +1 (858) 224-1092 +1 (858) 480-2411 skunszabo@organovo.com jessica@litldog.com ORGANOVO ANNOUNCES CEO TRANSITION Taylor J. Crouch Named Chief Executive
Read more →VIVSInvestor Contact: Press Contact: Steve Kunszabo Jessica Yingling Organovo Holdings, Inc. Little Dog Communications +1 (858) 224-1092 +1 (858) 344-8091 skunszabo@organovo.com jessica@litldog.com ORGANOVO PRICES APPROXIMAT
Investor Contact: Press Contact: Steve Kunszabo Jessica Yingling Organovo Holdings, Inc. Little Dog Communications +1 (858) 224-1092 +1 (858) 344-8091 skunszabo@organovo.com jessica@litldog.com ORGANOVO PRICES APPROXIMATELY $25 MILLION PUBLIC OFFERING OF COMMON ST
Read more →VIVSInvestor Contact: Press Contact: Steve Kunszabo Jessica Yingling Organovo Holdings, Inc. Little Dog Communications +1 (858) 224-1092 +1 (858) 344-8091 skunszabo@organovo.com jessica@litldog.com ORGANOVO ANNOUNCES SELECT
Investor Contact: Press Contact: Steve Kunszabo Jessica Yingling Organovo Holdings, Inc. Little Dog Communications +1 (858) 224-1092 +1 (858) 344-8091 skunszabo@organovo.com jessica@litldog.com ORGANOVO ANNOUNCES SELECT PRELIMINARY SECOND-QUARTER 2017 RESULTS; COMPANY
Read more →VIVSInvestor Contact: Press Contact: Steve Kunszabo Jessica Yingling Organovo Holdings, Inc. Little Dog Communications +1 (858) 224-1092 +1 (858) 480-2411 skunszabo@organovo.com jessica@litldog.com
Investor Contact: Press Contact: Steve Kunszabo Jessica Yingling Organovo Holdings, Inc. Little Dog Communications +1 (858) 224-1092 +1 (858) 480-2411 skunszabo@organovo.com jessica@litldog.com ORGANOVO APPOINTS TWO NEW MEMBERS TO BOARD OF DIRECTORS SAN DIEGO Aug
Read more →VIVSCONFIDENTIAL Organovo, Inc. 6275 Nancy Ridge Drive Suite 110 San Diego, CA 92121
13363 Caminito Mendiola On behalf of Organovo Inc., ( Organovo ) it is a great pleasure to extend you an offer of employment as, Chief Financial Officer, reporting to me. In making this offer, we are expressing our enthusiastic support for the skills and commitment you will bri
Read more →VIVSInvestor Contact: Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com Jessica Yingling Little Dog Communications +1 (858) 480-2411 jessica@litldog.com
Investor Contact: Press Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com Jessica Yingling Little Dog Communications +1 (858) 480-2411 jessica@litldog.com ORGANOVO TO BEGIN TRADING ON NASDAQ STOCK MARKET SAN DIEGO July 26, 2016 Organovo
Read more →VIVSInvestor Contact: Press Contact : Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com Jessica Yingling Little Dog Communications +1 (858) 480-2411 jessica@litldog.com ORGANOVO ANNOUNCES FISCAL
Investor Contact:Press Contact: Organovo Holdings, Inc. skunszabo@organovo.com Little Dog Communications ORGANOVO ANNOUNCES FISCAL THIRD-QUARTER RESULTS; COMPANY UPDATES FULL-YEAR FISCAL 2016 OUTLOOK AND AFFIRMS LONG-RANGE GUIDANCE SAN DIEGO, Ca. - February 8, 2016 - Organov
Read more →VIVSOrganovo Reports First-Quarter Fiscal 2016 Financial Results and Corporate Highlights
Organovo Reports First-Quarter Fiscal 2016 Financial Results and Corporate Highlights SAN DIEGO, August 10, 2015 -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo" or the "Company"), a three-dimensional biology company focused on delivering scientific and medical breakthrou
Read more →VIVSOrganovo Holdings, Inc. Prices $40 Million Public Offering of Common Stock
Organovo Holdings, Inc. Prices $40 Million Public Offering of Common Stock SAN DIEGO, June 18, 2015 Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo or the Company ) today announced the sale of 9,425,000 shares of its common stock in an underwritten public offering at a pric
Read more →VIVSOrganovo Reports Fiscal 2015 Financial Results, Corporate Highlights and Total Contract Bookings for exVive3D Human Liver Tissue
Organovo Reports Fiscal 2015 Financial Results, Corporate Highlights and Total Contract Bookings for exVive3D Human Liver Tissue SAN DIEGO, June 9, 2015 Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo or the Company ), a three-dimensional biology company focused on deliver
Read more →VIVSORGANOVO HOLDINGS, INC. PRE-ANNOUNCES PRELIMINARY FISCAL 2015 FOURTH QUARTER AND YEAR END FINANCIAL INFORMATION San Diego, Calif.
ORGANOVO HOLDINGS, INC. PRE-ANNOUNCES PRELIMINARY FISCAL 2015 FOURTH QUARTER AND YEAR END FINANCIAL INFORMATION San Diego, Calif., April 21, 2015-Organovo Holdings, Inc. (NYSE MKT: ONVO) today announced preliminary financial information (unaudited) for the fourth quarter and fi
Read more →VIVSOrganovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue
Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue SAN DIEGO, April 1, 2015 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, presented data on
Read more →VIVSOrganovo Provides Market Update
Organovo Provides Market Update SAN DIEGO, March 13, 2015 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO; "Organovo"), is providing the following market update: Organovo remains extremely excited about the early commercial success of our exVive3D Human Liver Tissue and
Read more →VIVSFORWARD LOOKING STATEMENTS Copyright 2015 Organovo Holdings, Inc. NYSE MKT: ONVO The Company cautions you that the statements included in this presentation that are not a description of historical facts are forward-looki
Copyright 2015, Organovo Holdings, Inc. This report is solely for the use of intended audience. No part of it may be circulated, quoted, or reproduced for distribution outside the organization without prior written approval from Organovo Holdings, Inc. Changing the Shape of Medic
Read more →VIVSOrganovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th Company invites individual and institutional investors as well as advisors to attend real-time, vi
Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th Company invites individual and institutional investors as well as advisors to attend real-time, virtual RetailInvestorConferences.com SAN DIEGO, February 2
Read more →VIVSOrganovo Holdings, Inc. 6275 Nancy Ridge Dr. San Diego, CA 92121
Organovo Holdings, Inc. 6275 Nancy Ridge Dr. Dear Fellow Shareholder, It s always a pleasure when I get to provide an update on Organovo, because of our steady and exciting movement forward. Our progress has recently been recognized by Organovo being named as one of FastCompa
Read more →VIVSOrganovo Holdings, Inc. Reports Second Quarter Results
Organovo Holdings, Inc. Reports Second Quarter Results SAN DIEGO, Feb. 9, 2015 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering pioneering 3D bioprinting technology, has reported its third quarter fi
Read more →VIVSOrganovo Appoints Dr. Kirk Malloy to Board of Directors
Organovo Appoints Dr. Kirk Malloy to Board of Directors SAN DIEGO, Dec. 8, 2014 /PRNewswire/ Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, announced today Kirk D. Malloy,
Read more →VIVSOrganovo to Present at the 26th Annual Piper Jaffray Healthcare Conference
Organovo to Present at the 26th Annual Piper Jaffray Healthcare Conference SAN DIEGO, Nov. 20, 2014 /PRNewswire/ Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has been inv
Read more →VIVSOrganovo Announces Commercial Release of the exVive3D Human Liver Tissue SAN DIEGO, (
Organovo Announces Commercial Release of the exVive3D Human Liver Tissue SAN DIEGO, (November 18, 2014) /PRNewswire/ Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today an
Read more →VIVSOrganovo Highlights Liver Toxicology Achievement, Reports Q1 Fiscal 2015 Results
Organovo Highlights Liver Toxicology Achievement, Reports Q1 Fiscal 2015 Results SAN DIEGO, August 12, 2014 Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering pioneering 3D bioprinting technology, has reported its fi
Read more →VIVSOrganovo Reports Fiscal 2014 Financial Results
Organovo Reports Fiscal 2014 Financial Results DIEGO, June 12, 2014 Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported its financial results for the fiscal year en
Read more →VIVSOrganovo Announces Pre-Release Availability of 3D Liver Contract Services 04/29/2014
Organovo Announces Pre-Release Availability of 3D Liver Contract Services SAN DIEGO, April 29, 2014 /PRNewswire/ Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announ
Read more →VIVSOrganovo Provides Guidance on Retail Investor Conference 03/28/2014
Organovo Provides Guidance on Retail Investor Conference SAN DIEGO, March 28, 2014 /PRNewswire/ Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today provided guidance on to
Read more →VIVSOrganovo Reports Q3 Fiscal 2014 Results, Provides Business Update
Organovo Reports Q3 Fiscal 2014 Results, Provides Business Update February 7, 2014 / PRNewswire/ Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported its third quart
Read more →VIVSOrganovo Announces First Delivery of 3D Liver Tissue to Key Opinion Leader 01/29/2014
Organovo Announces First Delivery of 3D Liver Tissue to Key Opinion Leader SAN DIEGO, January 29, 2014 /PRNewswire/ Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today ann
Read more →VIVSOrganovo Announces Collaboration with National Institutes of Health 01/14/2014 SAN DIEGO, CA and BETHESDA, Md.
Organovo Announces Collaboration with National Institutes of Health SAN DIEGO, CA and BETHESDA, Md., Jan. 14, 2014 /PRNewswire/ Organovo announced today that they are joining together with two institutes from the National Institutes of Health (NIH) to help scientists develop mo
Read more →VIVSOrganovo Provides Guidance on Upcoming Retail Investor Conference 11/20/2013
Organovo Provides Guidance on Upcoming Retail Investor Conference SAN DIEGO, November 20, 2013 /PRNewswire/ Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today provided gu
Read more →VIVSORGANOVO REPORTS Q2 FISCAL 2014 RESULTS
ORGANOVO REPORTS Q2 FISCAL 2014 RESULTS, PROVIDES BUSINESS UPDATE SAN DIEGO, Organovo Holdings, Inc. (NYSE MKT: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported its second quarter results and prov
Read more →VIVSOrganovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com September 12th Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK /
Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com September 12th Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK / September 9, 2013 Organovo Holdings, Inc. (NYSE MKT: ONVO) the San Dieg
Read more →VIVSORGANOVO
ORGANOVO TO LIST COMMON STOCK ON NYSE MKT SAN DIEGO, Organovo Holdings, Inc. (OTCQX: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, is pleased to announce that its common shares have been approved to list on the
Read more →VIVSOrganovo Appoints Tamar D. Howson to Board of Directors 06/10/2013 SAN DIEGO, Organovo Holdings, Inc. (OTCQX: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technolog
Organovo Appoints Tamar D. Howson to Board of Directors Inc. (OTCQX: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, today announced that Tamar D. Howson has been appointed to the Company s Board of Directors. Ms.
Read more →VIVSOrganovo Holdings, Inc. announces completion of 2.3 million outstanding warrant redemption
Organovo Holdings, Inc. announces completion of 2.3 million outstanding warrant SAN DIEGO, March 19, 2013, Organovo Holdings, Inc. (OTCQX: ONVO) ( Organovo ), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applica
Read more →VIVSOrganovo Reports 2012 Financial Results
Organovo Reports 2012 Financial Results SAN DIEGO, March 18, 2013 Organovo Holdings, Inc. (OTCQX: ONVO) ( Organovo ), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported on its financial results for the year ended Decem
Read more →VIVSChanging the Shape of Medical Research and Practice Keith Murphy Chairman and Chief Executive Officer Copyright 2013, Organovo Holdings, Inc. This report is solely for the use of intended audience. No part of it may be c
Changing the Shape of Medical Research and Practice Chairman and Chief Executive Officer Copyright 2013, Organovo Holdings, Inc. This report is solely for the use of intended audience. No part of it may be circulated, quoted, or reproduced for distribution outside the organizat
Read more →VIVSOrganovo Holdings, Inc. announces redemption of 2.4 million outstanding warrants 02/05/2013 SAN DIEGO Organovo Holdings, Inc. (OTCQX: ONVO) ( Organovo ), a creator and manufacturer of functional, three-dimensional human
Organovo Holdings, Inc. announces redemption of 2.4 million outstanding warrants Holdings, Inc. (OTCQX: ONVO) ( Organovo ), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, today announced its intention
Read more →VIVSOrganovo Partners With Autodesk Research to Develop 3D Bioprinting Software
Organovo Partners With Autodesk Research to Develop 3D Bioprinting Software SAN DIEGO, CA, December 18, 2012 Organovo Holdings, Inc. (OTCQX ONVO) ( Organovo ), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applic
Read more →VIVSORGANOVO REPORTS Q3 2012 FINANCIAL RESULTS
ORGANOVO REPORTS Q3 2012 FINANCIAL RESULTS, PROVIDES BUSINESS UPDATE SAN DIEGO, CA November 16, 2012 Organovo Holdings, Inc. (OTCQX: ONVO) ( Organovo ) a three-dimensional biology company focused on delivering breakthrough 3-D bioprinting technology, has reported on its financ
Read more →VIVSOrganovo Holdings, Inc. Joins
Organovo Holdings, Inc. Joins OTCQX SAN DIEGO, Oct. 8, 2012 /PRNewswire/ Organovo Holdings, Inc. (OTCQX: ONVO), a developer and manufacturer of functional human tissues using a novel three-dimensional bioprinting technology, announced today that it will begin trading on the hig
Read more →VIVSOrganovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd 07/30/2012 Download this Press Release ()
Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd Download this Press Release () NEW YORK, July 30, 2012 /PRNewswire/ Organovo Holdings, Inc. (OTCQB: ONVO) the San Diego-based regenerative medicine company focused on using its breakthroug
Read more →VIVSOrganovo Holdings Appoints James T. Glover to Board of Directors
Organovo Holdings Appoints James T. Glover to Board of Directors July 9, 2012 Organovo Holdings, Inc. (OTCQB: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, today announced that James T. Glover has been appointed
Read more →VIVSORGANOVO ANNOUNCES CLOSE OF $15.2 MILLION PRIVATE PLACEMENT TO ADVANCE 3D
ORGANOVO ANNOUNCES CLOSE OF $15.2 MILLION PRIVATE PLACEMENT TO ADVANCE 3D BIOPRINTING FOR MEDICAL APPLICATIONS SAN DIEGO, CA March 19, 2012 Organovo Holdings, Inc. (OTCQB: ONVO) ( Organovo ) today announced the final closing of an oversubscribed $15.2 million private placement.
Read more →VIVSOrganovo Named to MIT Technology Review s 2012 TR50 List of the World s Most Innovative Companies
Organovo Named to MIT Technology Review s 2012 TR50 List of the World s Most Innovative Companies SAN DIEGO, CA February 28, 2012 Organovo, Inc. (OTCQB: ONVO) has been included in the 2012 TR50, Technology Review s annual list of the world s most innovative technology companie
Read more →VIVSORGANOVO ANNOUNCES $6.5 MILLION PRIVATE PLACEMENT TO ADVANCE 3D
ORGANOVO ANNOUNCES $6.5 MILLION PRIVATE PLACEMENT TO ADVANCE 3D BIOPRINTING FOR MEDICAL APPLICATIONS SAN DIEGO, CA - February 14, 2012 - Organovo Holdings, Inc. (OTCQB: ONVO) ("Organovo") today announced the successful completion of a merger on February 8, 2012, with Organovo, I
Read more →Competitive Position
How VIVS ranks across every disease it competes inCompetitive Position is a premium feature
See how VIVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial